supp.fit

Electrolytes and Calcium: study protocols

22 study groups took Electrolytes together with Calcium. These are the doses the studies gave. They are not a recommendation.

Electrolytes: what the research found →

Dose per serving from research: Electrolytes

15 study groups in 10 studies say how much Electrolytes participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 25 mg to 50 mg and 100 mg to 250 mg, 27% of 15 study groups each.

Daily doseStudy groups
10 mg to 25 mg
2
25 mg to 50 mg
4
50 mg to 100 mg
1
100 mg to 250 mg
4
250 mg to 500 mg
0
500 mg to 1 g
1
1 g to 2.5 g
3

Dose per serving from research: Calcium

17 study groups in 10 studies say how much Calcium participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 71% of 17 study groups.

Daily doseStudy groups
250 mg to 500 mg
3
500 mg to 1 g
12
1 g to 2.5 g
2

Commonly used together

9 of 22 study groups took Electrolytes and Calcium with something else, but nothing that 3 or more different studies gave.

22 study groups

Study
Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial
1994 · slow-release sodium fluoride group · Women with postmenopausal osteoporosis
50 mg800 mg913 days54
Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy
1998 · Sodium fluoride · Postmenopausal women with osteoporosis and vertebral fractures
50 mg1 g2 years—
Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy
1998 · Monofluorophosphate, 200 mg/day · Postmenopausal women with osteoporosis and vertebral fractures
200 mg1 g2 years—
Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy
1998 · Monofluorophosphate, 150 mg/day · Postmenopausal women with osteoporosis and vertebral fractures
150 mg1 g2 years—
Impact of supplementation with bicarbonate on lower-extremity muscle performance in older men and women
2010 · potassium bicarbonate group · Healthy ambulatory men and postmenopausal women aged 50 years and older
67.5 mmol600 mg90 days—
Impact of supplementation with bicarbonate on lower-extremity muscle performance in older men and women
2010 · sodium bicarbonate group · Healthy ambulatory men and postmenopausal women aged 50 years and older
67.5 mmol600 mg90 days—
Impact of supplementation with bicarbonate on lower-extremity muscle performance in older men and women
2010 · potassium chloride group · Healthy ambulatory men and postmenopausal women aged 50 years and older
67.5 mmol600 mg90 days—
Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide
2016 · TPTD group · Postmenopausal women and men with osteoporosis; age range not stated
30 mg610 mg72 weeks153
Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide
2016 · Placebo group · Postmenopausal women and men with osteoporosis; age range not stated
30 mg610 mg72 weeks137
The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women
1993 · group 3 · Healthy early postmenopausal women; mean age 53.9 years
2 g—2 years10
Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study
1999 · MFP · Postmenopausal women aged 60–70 years
20 mg1 g96 weeks—
Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study
1999 · HRT+MFP · Postmenopausal women aged 60–70 years
20 mg1 g96 weeks—
Monofluorophosphate increases lumbar bone density in osteopenic patients: a double-masked randomized study
1995 · FC (sodium monofluorophosphate and calcium) · Patients aged 50–70 years with severe osteopenia and no previous vertebral fracture
200 mg1 g2 years—
In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study
1996 · MFP-Ca group · Adults aged 21–65 with asthma or other respiratory diseases who had received long-term corticosteroid treatment
200 mg1 g2 years—
Bioavailability of fluoride in postmenopausal women: comparative study between sodium fluoride and disodium monofluorophosphate-calcium carbonate
1992 · disodium monofluorophosphate-calcium carbonate (MFP-Ca) · Postmenopausal women aged 48–77 years without bone disease
100 mg1.25 g1 day10
Small bowel absorption of magnesium and calcium sulphate from a natural mineral water in subjects with ileostomy
2006 · High-mineral-content natural mineral water · Six subjects with ileostomy
7.7 mmol6.9 mmol2 days6
Effects of mineral composition of drinking water on risk for stone formation and bone metabolism in idiopathic calcium nephrolithiasis
1996 · Low-calcium mineral water · 21 patients with idiopathic calcium nephrolithiasis; age and sex not reported
0.5 mmol1 mmol30 days21
Effects of mineral composition of drinking water on risk for stone formation and bone metabolism in idiopathic calcium nephrolithiasis
1996 · Intermediate-calcium mineral water · 21 patients with idiopathic calcium nephrolithiasis; age and sex not reported
10 mmol6 mmol30 days21
Effects of mineral composition of drinking water on risk for stone formation and bone metabolism in idiopathic calcium nephrolithiasis
1996 · High-calcium, alkaline mineral water · 21 patients with idiopathic calcium nephrolithiasis; age and sex not reported
50 mmol20 mmol30 days21
Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine
1992 · Group II · Postmenopausal women with osteoporosis and at least one vertebral crush fracture
750 mg500 mg2 years—
Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis
1994 · phosphate/placebo · Postmenopausal women with vertebral compression fractures
2 g500 mg104 weeks—
Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis
1994 · phosphate/etidronate · Postmenopausal women with vertebral compression fractures
2 g500 mg104 weeks—
Electrolytes and Calcium: study protocols | supp.fit